These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15134823)

  • 21. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
    Coca SG; Perazella MA
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone blockade in patients with chronic heart failure.
    Pitt B
    Cardiol Clin; 2008 Feb; 26(1):15-21, v. PubMed ID: 18312902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design].
    Cacciatore G; Boccanelli A; Mureddu GF; Maggioni AP; Latini R; Masson S; de Simone G;
    Ital Heart J; 2005 May; 6 Suppl 1():66S-74S. PubMed ID: 15945301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone: from integrative physiology to cellular biology and back.
    Ertl G
    Eur J Clin Invest; 2004 Oct; 34(10):653-5. PubMed ID: 15473889
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of spironolactone on C-reactive protein levels in patients with heart disease.
    Godfrey V; Farquharson CA; Macdonald JE; Yee KM; Struthers AD
    Int J Cardiol; 2007 Apr; 117(2):282-4. PubMed ID: 16899309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
    Greenberg B; Zannad F; Pitt B
    Am J Cardiol; 2006 May; 97(10A):34F-40F. PubMed ID: 16698333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies.
    Siddiqui A; Kowey PR
    Curr Opin Cardiol; 2006 Sep; 21(5):517-25. PubMed ID: 16900017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Curriculum in cardiology: Integrated diagnosis and management of diastolic heart failure (Am Heart J 2007;153:189-200).
    Jolobe OM
    Am Heart J; 2007 Jul; 154(1):e5; author reply e7. PubMed ID: 17584543
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic heart failure: an overview of conventional treatment versus novel approaches.
    Landmesser U; Drexler H
    Nat Clin Pract Cardiovasc Med; 2005 Dec; 2(12):628-38. PubMed ID: 16306919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone and progression of kidney disease.
    Cortinovis M; Perico N; Cattaneo D; Remuzzi G
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):133-43. PubMed ID: 19171691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction. II. Diuretics.
    Fortuna P; Reis I; Ascenção R; Carneiro AV
    Rev Port Cardiol; 2008; 27(7-8):977-89. PubMed ID: 18959094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
    Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
    Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation.
    Bauersachs J
    Eur J Clin Invest; 2004 Oct; 34(10):649-52. PubMed ID: 15473888
    [No Abstract]   [Full Text] [Related]  

  • 37. Aldosterone-induced vasculopathy: a new reversible cause of cardiac death.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):211-4. PubMed ID: 11881125
    [No Abstract]   [Full Text] [Related]  

  • 38. [Secretion and inactivation of aldosterone in hydropic heart insufficiency].
    Kaufmann W; Steiner B; Dürr F; Meurer KA
    Verh Dtsch Ges Kreislaufforsch; 1969; 35():419-24. PubMed ID: 5380623
    [No Abstract]   [Full Text] [Related]  

  • 39. Distribution, conjugation, and excretion of labeled aldosterone in congestive heart failure and in controls with normal circulation: development and testing of a model with an analog computer.
    Cheville RA; Luetscher JA; Hancock EW; Dowdy AJ; Nokes GW
    J Clin Invest; 1966 Aug; 45(8):1302-16. PubMed ID: 5923702
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of cross talk between superoxide and NO in the energy metabolism and pathogenesis of vasogenic tissue injury.
    Inoue M
    J Toxicol Sci; 1996 Dec; 21(5):289. PubMed ID: 9035037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.